pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2010: Net Loss of $0.15 Per Share

pSivida Corp. PSDV, a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today announced financial results for its second quarter and six months ended December 31, 2010. The Company reported a consolidated net loss of $2.7 million, or $0.15 per share, for the second quarter ended December 31, 2010, compared to a consolidated net loss of $24,000, or $0.00 per share, for the second quarter of the prior year.